甲基化
生物
精氨酸
甲基转移酶
细胞生物学
聚腺苷酸
DNA甲基化
癌症研究
蛋白质精氨酸甲基转移酶5
生物化学
劈理(地质)
细胞生长
分子生物学
细胞培养
下调和上调
蛋氨酸
细胞
HEK 293细胞
癌细胞
表观遗传学
作者
Llywelyn Griffith,Charlotte Capitanchik,Shaun Moore,Anca M. Farcas,Mags Gwynne,Martina Pedna,Ivana Vukšinić,Veronika Bračič,Karen Davey,D. Marc Jones,Anob M. Chakrabarti,Dimitris Lagos,Jelena Urosevic,James T. Lynch,Jernej Ule
标识
DOI:10.1016/j.molcel.2026.10.003
摘要
Protein arginine methyltransferases (PRMTs) are promising anti-cancer targets, but their tumorigenic mechanisms remain incompletely understood. Here, we show that arginine methylation drives global 3′UTR shortening, thereby promoting oncogenic short isoforms. Inhibition of asymmetric dimethylation reverses this shift, with combined inhibition of asymmetric and symmetric dimethylation (DMAi) producing an even greater effect across human cancer cell lines, patient-derived organoids, and activated murine T cells, while also counteracting the shortening induced by reduced CFIm25 expression. Arginine methylation promotes PCF11 association with the cleavage and polyadenylation machinery, enabling efficient processing of weak proximal poly(A) sites within transcripts characterized by high GC content, large distances between alternative poly(A) sites, and a position-dependent sequence code. These findings establish physiologic roles of PRMTs in promoting 3′UTR shortening, which could be exploited for patient stratification of PRMT-targeting therapies in oncology and immune-related diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI